News Daily News In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report Michael O'Riordan January 27, 2022
News Daily News Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse Todd Neale January 21, 2022
News Daily News As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control Caitlin E. Cox January 10, 2022
News Daily News AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD Caitlin E. Cox December 28, 2021
News Daily News Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF L.A. McKeown December 07, 2021
News Daily News FDA Green-lights Empagliflozin for HF With Reduced Ejection Fraction Michael O'Riordan August 19, 2021
News Daily News Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results Todd Neale July 06, 2021
News Daily News Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors Michael O'Riordan June 16, 2021
News Daily News Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care Shelley Wood May 27, 2021
News Daily News Diabetes Duration and Meds Don’t Impact Ticagrelor Effects in THEMIS Todd Neale May 14, 2021
News Daily News ACC’s HFrEF Update Includes ARNI, SGLT2 Inhibitor Trials Plus Tips for Care L.A. McKeown January 11, 2021
News Daily News AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More Shelley Wood December 17, 2020
News Daily News Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors Shelley Wood September 30, 2020
News Daily News VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks Michael O'Riordan September 24, 2020
News Daily News New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts Michael O'Riordan August 06, 2020
News Daily News Rosuvastatin-Canagliflozin Combo May Be Toxic, Case Suggests Todd Neale August 03, 2020